相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
Elena Mazza et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice
Ferdinando De Vita et al.
BMC CANCER (2016)
Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial
Li Zhang et al.
LANCET (2016)
Profiling ribonucleotide and deoxyribonucleotide pools perturbed by gemcitabine in human non-small cell lung cancer cells
Jian-Ru Guo et al.
SCIENTIFIC REPORTS (2016)
Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study
Roberto Petrioli et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Phase I/II Study of Clofarabine, Etoposide, and Mitoxantrone in Patients With Refractory or Relapsed Acute Leukemia
Kamal K. S. Abbi et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2015)
Phase 1/2 Trials of Temozolomide, Motexafin Gadolinium, and 60-Gy Fractionated Radiation for Newly Diagnosed Supratentorial Glioblastoma Multiforme: Final Results of RTOG 0513
David G. Brachman et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2015)
Drug-Resistant Urothelial Cancer Cell Lines Display Diverse Sensitivity Profiles to Potential Second-Line Therapeutics
Stefan Vallo et al.
TRANSLATIONAL ONCOLOGY (2015)
Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies
Y. Aye et al.
ONCOGENE (2015)
Transplantation of CD3/CD19 depleted allografts from haploidentical family donors in paediatric leukaemia
Peter Lang et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms
Joshua F. Zeidner et al.
HAEMATOLOGICA (2014)
First FDA Approval of Dual Anti-HER2 Regimen: Pertuzumab in Combination with Trastuzumab and Docetaxel for HER2-Positive Metastatic Breast Cancer
Gideon M. Blumenthal et al.
CLINICAL CANCER RESEARCH (2013)
Targeting ribonucleotide reductase for cancer therapy
Jimin Shao et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2013)
A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors
Amir Mortazavi et al.
INVESTIGATIONAL NEW DRUGS (2013)
Development of Ribonucleotide Reductase Inhibitor: A Review on Structure Activity Relationships
Narayana S. H. N. Moorthy et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2013)
Oral clofarabine for relapsed/refractory non-Hodgkin lymphomas: results of a phase 1 study
Jeremy S. Abramson et al.
LEUKEMIA & LYMPHOMA (2013)
A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma
P. L. Zinzani et al.
ANNALS OF ONCOLOGY (2012)
A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer
C. Manegold et al.
ANNALS OF ONCOLOGY (2012)
Hepatocellular Carcinoma Detection by Gallium Scan and Subsequent Treatment by Gallium Maltolate: Rationale and Case Study
Lawrence R. Bernstein et al.
Anti-Cancer Agents in Medicinal Chemistry (2012)
A Dose Escalation and Pharmacodynamic Study of Triapine and Radiation in Patients With Locally Advanced Pancreas Cancer
Ludmila Katherine Martin et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2012)
Clofarabine Plus Cytarabine Compared With Cytarabine Alone in Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia: Results From the CLASSIC I Trial
Stefan Faderl et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Concomitant chemoradiotherapy using low-dose weekly gemcitabine versus low-dose weekly paclitaxel in locally advanced head and neck squamous cell carcinoma: a phase III study
Amal Ahmed-Fouad Halim et al.
MEDICAL ONCOLOGY (2012)
A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers
J. K. Salama et al.
ANNALS OF ONCOLOGY (2011)
Phase 2 Trial of Concurrent 5-Fluorouracil, Hydroxyurea, Cetuximab, and Hyperfractionated Intensity-Modulated Radiation Therapy for Locally Advanced Head and Neck Cancer
Johnny Kao et al.
CANCER (2011)
A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer
Srikala S. Sridhar et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Prognostic but not predictive role of platelet-derived growth factor receptors in patients with recurrent glioblastoma
Janna Paulsson et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies
Anne M. Traynor et al.
INVESTIGATIONAL NEW DRUGS (2011)
Randomized Phase II Study Comparing Gemcitabine Plus Dacarbazine Versus Dacarbazine Alone in Patients With Previously Treated Soft Tissue Sarcoma: A Spanish Group for Research on Sarcomas Study
Xavier Garcia-del-Muro et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Phase III, Open-Label, Randomized Study Comparing Concurrent Gemcitabine Plus Cisplatin and Radiation Followed by Adjuvant Gemcitabine and Cisplatin Versus Concurrent Cisplatin and Radiation in Patients With Stage IIB to IVA Carcinoma of the Cervix
Alfonso Duenas-Gonzalez et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A Phase III Randomized Trial of Gemcitabine-Oxaliplatin versus Carboplatin-Paclitaxel as First-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer
Charles H. Weissman et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Multicenter Phase II Trial of Motexafin Gadolinium and Pemetrexed for Second-Line Treatment in Patients with Non-small Cell Lung Cancer
Martin J. Edelman et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Phase I and Pharmacokinetic Study of IV Vinflunine in Combination with Gemcitabine for Treatment of Advanced Non-small Cell Lung Cancer in Chemonaive Patients
Caroline Tournoux-Facon et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Phase I trial and pharmacokinetic study of high-dose clofarabine and busulfan and allogeneic stem cell transplantation in adults with high-risk and refractory acute leukemia
S. S. Farag et al.
LEUKEMIA (2011)
A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172)
C. Tom Kouroukis et al.
LEUKEMIA & LYMPHOMA (2011)
Structural basis for allosteric regulation of human ribonucleotide reductase by nucleotide-induced oligomerization
James Wesley Fairman et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2011)
Report of a Phase II Study of Clofarabine and Cytarabine in De Novo and Relapsed and Refractory AML Patients and in Selected Elderly Patients at High Risk for Anthracycline Toxicity
Edward Agura et al.
ONCOLOGIST (2011)
Single-Unit Umbilical Cord Blood Transplantation from Unrelated Donors in Adult Patients with Chronic Myelogenous Leukemia
Jaime Sanz et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2010)
Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia
Anjali S. Advani et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
A phase II trial of TriapineA® (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503
Anne M. Traynor et al.
INVESTIGATIONAL NEW DRUGS (2010)
Phase II Study of Clofarabine Monotherapy in Previously Untreated Older Adults With Acute Myeloid Leukemia and Unfavorable Prognostic Factors
Hagop M. Kantarjian et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase III Trial of Carboplatin Plus Paclitaxel With or Without Gemcitabine in First-Line Treatment of Epithelial Ovarian Cancer
Andreas du Bois et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Comparison of Cladribine Plus Cyclophosphamide With Fludarabine Plus Cyclophosphamide As First-Line Therapy for Chronic Lymphocytic Leukemia: A Phase III Randomized Study by the Polish Adult Leukemia Group (PALG-CLL3 Study)
Tadeusz Robak et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Randomized Phase III Trial on Gemcitabine Versus Mytomicin in Recurrent Superficial Bladder Cancer: Evaluation of Efficacy and Tolerance
Raffaele Addeo et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide
Gregor Dresemann et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
M. Hallek et al.
LANCET (2010)
A phase II study of low dose intravenous clofarabine for elderly patients with myelodysplastic syndrome who have failed 5-azacytidine
Seah H. Lim et al.
LEUKEMIA & LYMPHOMA (2010)
A novel gallium compound synergistically enhances bortezomib-induced apoptosis in mantle cell lymphoma cells
Christopher R. Chitambar et al.
LEUKEMIA RESEARCH (2010)
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Mark E. Davis et al.
NATURE (2010)
Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane®) in combination with gemcitabine in patients with metastatic breast cancer (N0531)
V. Roy et al.
ANNALS OF ONCOLOGY (2009)
Phase II study of 3-AP Triapine in patients with recurrent or metastatic head and neck squamous cell carcinoma
C. M. Nutting et al.
ANNALS OF ONCOLOGY (2009)
Mechanism of inhibition of ribonucleotide reductase with motexafin gadolinium (MGd)
Farnaz Zahedi Avval et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2009)
Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma
Paul M. Barr et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Phase I Pharmacokinetic Study of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Vatalanib (PTK787) Plus Imatinib and Hydroxyurea for Malignant Glioma
David A. Reardon et al.
CANCER (2009)
A phase I study of Triapine® in combination with doxorubicin in patients with advanced solid tumors
William R. Schelman et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study
Stephen I. Shibata et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma
Kensei Tobinai et al.
CANCER SCIENCE (2009)
The Novel Expanded Porphyrin, Motexafin Gadolinium, Combined with [90Y]Ibritumomab Tiuxetan for Relapsed/Refractory Non-Hodgkin's Lymphoma: Preclinical Findings and Results of a Phase I Trial
Andrew M. Evens et al.
CLINICAL CANCER RESEARCH (2009)
MOTEXAFIN GADOLINIUM COMBINED WITH PROMPT WHOLE BRAIN RADIOTHERAPY PROLONGS TIME TO NEUROLOGIC PROGRESSION IN NON-SMALL-CELL LUNG CANCER PATIENTS WITH BRAIN METASTASES: RESULTS OF A PHASE III TRIAL
Minesh P. Mehta et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2009)
Results of a Phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma
Lawrence E. Garbo et al.
INVESTIGATIONAL NEW DRUGS (2009)
5-Year Survival in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia in a Randomized, Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen
Susan O'Brien et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia
Sima Jeha et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase III Study of Gemcitabine Plus Docetaxel Compared With Capecitabine Plus Docetaxel for Anthracycline-Pretreated Patients With Metastatic Breast Cancer
Stephen Chan et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A Phase I/II Study of GTI-2040 Plus Docetaxel as Second-Line Treatment in Advanced Non-small Cell Lung Cancer A Study of the PMH Phase II Consortium
Natasha B. Leighl et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
The First Targeted Delivery of siRNA in Humans via a Self-Assembling, Cyclodextrin Polymer-Based Nanoparticle: From Concept to Clinic
Mark E. Davis
MOLECULAR PHARMACEUTICS (2009)
A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia
N. Hijiya et al.
LEUKEMIA (2009)
Effects of motexafin gadolinium in a phase II trial in refractory chronic lymphocytic leukemia
Thomas S. Lin et al.
LEUKEMIA & LYMPHOMA (2009)
Phase I study of biweekly oxaliplatin, gemcitabine and capecitabine in patients with advanced upper gastrointestinal malignancies
B. R. Tan et al.
ANNALS OF ONCOLOGY (2008)
Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia
Rebecca B. Klisovic et al.
CLINICAL CANCER RESEARCH (2008)
Motexafin gadolinium for the treatment of metastatic renal cell carcinoma: Phase II study results
Robert J. Amato et al.
CLINICAL GENITOURINARY CANCER (2008)
Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia
Olatoyosi M. Odenike et al.
INVESTIGATIONAL NEW DRUGS (2008)
Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia
Apostolia M. Tsimberidou et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer
Tanguy Y. Seiwert et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer
Giorgio Vittorio Scagliotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Sequential oral hydroxyurea and intravenous cytosine arabinoside in refractory childhood acute leukemia - A pediatric oncology group phase 1 study
Ronald Dubowy et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2008)
A Phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine((R))) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders
Judith E. Karp et al.
LEUKEMIA RESEARCH (2008)
Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML
Alison R. Walker et al.
LEUKEMIA RESEARCH (2008)
Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: A Children's Oncology Group phase I study
Kristin A. Bradley et al.
NEURO-ONCOLOGY (2008)
Hydroxyurea for the treatment of sickle cell anemia
Orah S. Platt
NEW ENGLAND JOURNAL OF MEDICINE (2008)
A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine®) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells
Brigette Ma et al.
INVESTIGATIONAL NEW DRUGS (2008)
A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma
Walter M. Stadler et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
A phase II study of cisplatin preceded by a 12-h continuous infusion of concurrent hydroxyurea and cytosine arabinoside (Ara-C) for adult patients with malignant gliomas (Southwest Oncology Group S9149)
Lode J. Swinnen et al.
JOURNAL OF NEURO-ONCOLOGY (2008)
A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma
A. Duffy et al.
ANNALS OF ONCOLOGY (2008)
Gemcitabine plus docetaxel as first-line biweekly therapy in locally advanced and/or metastatic urothelial carcinoma: a phase II study
Bruno Neri et al.
ANTI-CANCER DRUGS (2007)
Results of the phase I dose-escalating study of motexafin gadolinium with standard radiotherapy in patients with glioblastoma multiforme
Judith M. Ford et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2007)
Phase II study of triapinea® in patients with metastatic renal cell carcinoma:: A trial of the national cancer institute of canada clinical trials group (NCIC IND.161)
Jennifer J. Knox et al.
INVESTIGATIONAL NEW DRUGS (2007)
Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer
Rachel R. Riechelmann et al.
CANCER (2007)
Bortezomib for the treatment of mantle cell lymphoma
Robert C. Kane et al.
CLINICAL CANCER RESEARCH (2007)
A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias
Judith E. Karp et al.
BLOOD (2007)
Phase I and pharmacokinetic study of Triapine®, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies
Ivana Gojo et al.
LEUKEMIA RESEARCH (2007)
Development of gallium compounds for treatment of lymphoma: Gallium maltolate, a novel hydroxypyrone gallium compound, induces apoptosis and circumvents lymphoma cell resistance to gallium nitrate
Christopher R. Chitambar et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
Phase I trial of motexafin gadolinium in combination with docetaxel and cisplatin for the treatment of non-small cell lung cancer
William N. William et al.
JOURNAL OF THORACIC ONCOLOGY (2007)
Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer
David G. Mutch et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Gary Hudes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas
Annick Desjardins et al.
JOURNAL OF NEURO-ONCOLOGY (2007)
Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA
Jeremy D. Heidel et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
RNA interference targeting the R2 subunit of ribonucleotide reductase inhibits growth of tumor cells in vitro and in vivo
Tina M. Avolio et al.
ANTI-CANCER DRUGS (2007)
Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer - A Randomized controlled trial
Helmut Oettle et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Didox, a ribonucleotide reductase inhibitor, induces apoptosis and inhibits DNA repair in multiple myeloma cells
N. Raje et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Ribonucleotide reductase inhibitors and future drug design
J. Shao et al.
CURRENT CANCER DRUG TARGETS (2006)
Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia
S Jeha et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers
RK Ramanathan et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2006)
Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage II and IV low-grade malignant non-Hodgkin's lymphoma
A Hagenbeek et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
A ferrous-Triapine complex mediates formation of reactive oxygen species chat inactivate human ribonucleotide reductase
JM Shao et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Potentiation of the activity of cisplatin and cyclophosphamide by trimidox, a novel ribonucleotide reductase inhibitor, in leukemia-bearing mice
L Novotny et al.
CANCER LETTERS (2006)
Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia
BF Eichhorst et al.
BLOOD (2006)
Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients
D Russo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Ribonucleotide reductase inhibitors enhance cidofovir-induced apoptosis in EBV-positive nasopharyngeal carcinoma xenografts
N Wakisaka et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia
CN Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors
AA Desai et al.
ANNALS OF ONCOLOGY (2005)
Phase I dose-escalation study of tezacitabine in combination with 5-fluorouracil in patients with advanced solid tumors
JC Bendell et al.
CANCER (2005)
Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer
J Pfisterer et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2005)
Motexafin gadolinium generates reactive oxygen species and induces apoptosis in sensitive and highly resistant multiple myeloma cells
AM Evens et al.
BLOOD (2005)
Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study
J Holowiecki et al.
LEUKEMIA (2004)
Phase II clinical trial of parenteral hydroxyurea in combination with fluorouracil, interferon and filgrastim in the treatment of advanced pancreatic, gastric and neuroendocrine tumors
A Kaubisch et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2004)
Combination chemotherapy of BCNU and Didox acts synergystically in 9L glioma cells
Z Horvath et al.
NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS (2004)
Synergistic cytotoxicity of the ribonucleotide reductase inhibitor didox (3,4-dihydroxy-benzohydroxamic acid) and the alkylating agent carmustine (BCNU) in 9L rat gliosarcoma cells and DAOY human medulloblastoma cells
Z Horvath et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2004)
A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases
OM Odenike et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2004)
Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: Results of a randomized phase III trial
CA Meyers et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Motexafin gadolinium: a redox-active tumor selective agent for the treatment of cancer
AM Evens
CURRENT OPINION IN ONCOLOGY (2004)
Durable response but prolonged cytopenia after cladribine treatment in relapsed patients with indolent non-Hodgkin's lymphomas: Results of a Japanese phase II study
M Ogura et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2004)
Phase I and pharmacodynamic study of Triapine®, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia
FJ Giles et al.
LEUKEMIA RESEARCH (2003)
Randomized comparison of interferon α and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II):: prolongation of survival by the combination of interferon α and hydroxyurea
R Hehlmann et al.
LEUKEMIA (2003)
Combined effects of temozolomide and the ribonucleotide reductase inhibitors didox and trimidox in malignant brain tumor cells
M Figul et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2003)
Dose escalation study of tezacitabine in combination with cisplatin in patients with advanced cancer
KT Flaherty et al.
CANCER (2003)
Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers
HM Kantarjian et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine:: A phase II study
G Jäger et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Didox (A novel ribonucleotide reductase inhibitor) overcomes bcl-2 mediated radiation resistance in prostate cancer cell line PC-3
MS Inayat et al.
CANCER BIOLOGY & THERAPY (2002)
Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: Centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points
MP Mehta et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Trimidox, an inhibitor of ribonucleotide reductase, synergistically enhances the inhibition of colony formation by Ara-C in HL-60 human promyelocytic leukemia cells
M Fritzer-Szekeres et al.
BIOCHEMICAL PHARMACOLOGY (2002)
Randomized phase II trial of either fluorouracil, parenteral hydroxyurea, interferon-α-2a, and filgrastim or doxorubicin/docetaxel in patients with advanced gastric cancer with qualityof-life assessment:: Eastern cooperative oncology group study E6296
S Wadler et al.
CANCER JOURNAL (2002)
Cellular and clinical pharmacology of fludarabine
V Gandhi et al.
CLINICAL PHARMACOKINETICS (2002)
Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases
P Carde et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Molecular remission following high-dose hydroxyurea and fludarabine plus cytarabine in a patient with simultaneous acute myeloid leukemia and low-grade lymphoma
E Montefusco et al.
LEUKEMIA & LYMPHOMA (2001)
Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.
KR Rai et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
The ribonucleotide reductase-inhibitor trimidox induces c-myc and apoptosis of human ovarian carcinoma cells
G Rosenberger et al.
LIFE SCIENCES (2000)
Trimidox, an inhibitor of ribonucleotide reductase, induces apoptosis and activates caspases in HL-60 promyelocytic leukemia cells
M Fritzer-Szekeres et al.
EXPERIMENTAL HEMATOLOGY (2000)
Triapine (3-aminopyridine-2-carboxaldehydethiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity
RA Finch et al.
BIOCHEMICAL PHARMACOLOGY (2000)
A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage
H Tanaka et al.
NATURE (2000)
A pharmacokinetic and phase II study of gallium nitrate in patients with non-small cell lung cancer
LK Webster et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2000)
Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer
AB Sandler et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
分享论文
